Loading patent…
OwnerAnderson Ryaninventor
Estimating the term…
A method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, such as colorectal cancer, which comprises one of: the administration of ZD6126 in combination with 5-FU; the administration of ZD6126 in combination with CIT-11; and the administration of ZD6126 in combination with 5-FU and CPT-11. Also claimed are pharmaceutical compositions and kits comprising one of ZD6126 and CPT-11; and ZD6126 and 5-FU and CPT-11. Further claimed is use of one of: ZD6126 and 5-FU; ZD6126 and CPT-11; and ZD6126 and 5-FU and CPT-11, in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal which is optionally being treated with ionising radiation.
Use of ZD6126 or a pharmaceutically acceptable salt thereof and one of:
Use according to any one of the preceding claims wherein the ZD6126 or a pharmaceutically acceptable salt thereof is used with 5-FU.
Use according to any one of the preceding claims wherein the warm-blooded animal is being treated with ionising radiation.
Use according to any one of the preceding claims wherein the ZD6126 or a pharmaceutically acceptable salt thereof is administered to the warm-blooded animal in divided doses.
A pharmaceutical composition comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU in association with a pharmaceutically acceptable excipient or carrier.
A pharmaceutical composition comprising ZD6126 or a pharmaceutically acceptable salt thereof, and CPIT-11 in association with a pharmaceutically acceptable excipient or carrier.
A pharmaceutical composition comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
A kit comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU.
A kit comprising ZD6126 or a pharmaceutically acceptable salt thereof, and CPT-11.
A kit comprising ZD6126 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11.
A method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:
A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:
Dependencies are inferred from the claim text.